Latest news with #REC603
India Gazette
01-07-2025
- Health
- India Gazette
BE to manufacture HPV9 vaccine for India, UNICEF and PAHO tender markets
Hyderabad (Telangana) [India], July 1 (ANI): Jiangsu Recbio Technology Company Limited ( announced that they have entered into a licensing cooperation agreement, and have commenced the technology transfer of their Recombinant 9-valent HPV (HPV9) vaccine, REC603, to Biological E. Limited (BE), a leading Indian vaccine and pharmaceutical company. Recbio will provide BE with Drug Substance (DS) and transfer technology to formulate, fill, and package vaccines. It will also include technology transfer for DS production at an appropriate time in the future. According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF & PAHO tenders in other markets. The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. HPV is a group of over 200 known viruses, some of which are classified as high-risk due to their potential to cause cancer. While most HPV infections are controlled by the body's immune system, persistent infections with high-risk HPV types can lead to cervical cancer and other malignancies affecting the vulva, vagina, mouth, throat, penis, and anus. In 2019 alone, HPV was linked to an estimated 620,000 cancer cases in women and 70,000 in men. Preventive vaccination, alongside HPV screening and treatment of pre-cancerous lesions, is a key strategy in reducing the global burden of HPV-related cancers. Cervical cancer is the fourth leading cause of cancer-related deaths among women worldwide. The 9-valent HPV vaccine is effective in preventing around 90 percent of cervical cancer and 90 percent of anal and genital warts. Recbio's core product, REC603, is for people ranging from 9 to 45 years old and is currently in the crucial Phase III clinical trials in China. Following the signing of the technology license agreement, Recbio has begun transferring the necessary technical knowledge, materials, and expertise to BE to produce the HPV9 vaccine. Recbio will continue to support BE in clinical development and regulatory approvals to ensure a seamless transition. This collaboration comes at a crucial time, as the global demand for cervical cancer prevention is at an all-time high. By leveraging BE's advanced manufacturing capabilities, this partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets. BE will begin large-scale manufacturing of the HPV9 vaccine once the Technology transfer is completed. This collaboration marks a significant milestone for Recbio in entering the Indian and international markets, highlighting its potential in the innovative vaccine field. Dr. Liu Yong, Founder, Chairman, and CEO of Recbio, stated, 'We are delighted to collaborate with Biological E. Limited. This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India, and jointly make greater contributions to global public health.' Mahima Datla, Managing Director, Biological E. Limited, said: 'We are pleased to partner with Recbio to bring the HPV9 vaccine to India and other countries. This collaboration aligns with our commitment to improving global health by making essential vaccines more accessible and affordable as well as to promote a lasting legacy of innovation and stewardship. We, along with Recbio, are committed to creating a healthier and more robust future by ensuring that this life-saving vaccine is delivered to those who need it the most.' (ANI)
Time of India
01-07-2025
- Health
- Time of India
Biological E, Recbio ink pact to make HP9 vax in India
HYDERABAD: Biopharma company Biological E Ltd (BE) entered into a licensing cooperation agreement with Chinese biopharma player Jiangsu Recbio Technology Company Limited for the latter's recombinant 9-valent Human Papillomavirus (HPV9) vaccine, REC603. The HPV9 vaccine has been designed to protect against nine types of HPV, including those responsible for cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. As part of the agreement, Recbio will provide BE with the drug substance (DS) and transfer technology to formulate, fill, and package vaccines. BE will get exclusive rights to commercialise the vaccine in India and also participate in United Nations Children's Fund (UNICEF) and Pan American Health Organisation (PAHO) tenders in other markets. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad Get the latest lifestyle updates on Times of India, along with Doctor's Day 2025 , messages and quotes!
New Indian Express
01-07-2025
- Health
- New Indian Express
Recbio, Biological E ink deal for HPV9 vaccine
HYDERABAD: Jiangsu Recbio Technology Co. Ltd, a leading Chinese biopharmaceutical firm, has entered into a licensing and technology transfer agreement with Hyderabad-based Biological E Limited (BE) for its Recombinant 9-valent HPV (HPV9) vaccine, REC603. The HPV9 vaccine is designed to protect against nine strains of Human Papillomavirus, including those linked to cervical, vulvar, vaginal, anal, oropharyngeal cancers and genital warts. Under the agreement, BE will receive exclusive rights to commercialise the vaccine in India and participate in global tenders by UNICEF and PAHO. According to a release, Recbio will supply the Drug Substance (DS) and transfer formulation, filling and packaging technologies to BE. DS production technology will also be transferred at a later stage. Recbio has started sharing the necessary technical expertise, materials and knowledge with BE to begin local production. It will also support BE through clinical development and regulatory approvals. The partnership aims to meet the growing global demand for cervical cancer prevention, the release said, adding that large-scale manufacturing will begin after the technology transfer is complete. Dr Liu Yong, Recbio's chairman and CEO, called the deal a major step in global expansion. Mahima Datla, MD of BE, said the partnership reflects their commitment to making life-saving vaccines more accessible and affordable.
The Hindu
30-06-2025
- Business
- The Hindu
Biological E. to produce Jiangsu Recbio Tech's HPV9 vaccine REC603
Hyderabad-based vaccine maker Biological E. will produce Chinese biopharmaceutical firm Jiangsu Recbio Technology Company's recombinant 9-valent HPV (HPV9) vaccine REC603 under a licensing cooperation agreement the companies announced on Monday. The Hong Kong stock exchange listed Recbio, under the agreement, will provide BE with drug substance (DS) and transfer technology to formulate, fill and package the vaccines. Technology transfer for the DS production will be given at an appropriate time in future, the companies said in a release. BE will receive exclusive right to commercialise the vaccine in India and participate in UNICEF and PAHO tenders in other markets. It will begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed. The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal and oropharyngeal cancers as well as genital warts. Following the license agreement, Recbio has started transferring necessary technical knowledge, materials and expertise to BE for producing the vaccine. It will continue to support BE in clinical development and regulatory approvals. Their collaboration comes at a time when the global demand for cervical cancer prevention is at an all-time high. By leveraging BE's advanced manufacturing capabilities, their partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets, the companies said. 'This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India and jointly make greater contributions to global public health,' Founder, Chairman and CEO of Recbio Liu Yong said. The Chinese firm has a portfolio of at least 10 high-value innovative vaccines covering major disease areas such as cervical cancer, herpes zoster and respiratory syncytial virus. REC603, one of its core products, is for people aged 9-45 years and currently in the phase III clinical trials in China. BE Managing Director Mahima Datla the company and Recbio are committed to ensure the life-saving vaccine is delivered to those who need it the most.
